Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study

Chimeric antigen receptor (CAR) T-cell therapy is a promising approach for some relapse/refractory hematological B-cell malignancies; however, in most patients, cytokine release syndrome (CRS) may occur. CRS is associated with acute kidney injury (AKI) that may affect the pharmacokinetics of some be...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chun, Cojutti, Pier Giorgio, Giannella, Maddalena, Roberto, Marcello, Casadei, Beatrice, Cristiano, Gianluca, Papayannidis, Cristina, Vianelli, Nicola, Zinzani, Pier Luigi, Viale, Pierluigi, Bonifazi, Francesca, Pea, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059857/
https://www.ncbi.nlm.nih.gov/pubmed/36986882
http://dx.doi.org/10.3390/pharmaceutics15031022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059857/
https://www.ncbi.nlm.nih.gov/pubmed/36986882
http://dx.doi.org/10.3390/pharmaceutics15031022

Ejemplares similares